The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 26005524 |
147 |
Discovery of MK-1421, a Potent, Selective sstr3 Antagonist, as a Development Candidate for Type 2 Diabetes. |
Merck Research Laboratories |
| 25050159 |
71 |
Investigation of Cardiovascular Effects of Tetrahydro-ß-carboline sstr3 antagonists. |
Merck Research Laboratories |
| 24944745 |
75 |
Diamine Derivatives as Novel Small-Molecule, Potent, and Subtype-Selective Somatostatin SST3 Receptor Agonists. |
Merck Research Laboratories |
| 24900499 |
67 |
The Discovery of MK-4256, a Potent SSTR3 Antagonist as a Potential Treatment of Type 2 Diabetes. |
TBA |
| 24900466 |
55 |
Stimulation of Glucose-Dependent Insulin Secretion by a Potent, Selective sst3 Antagonist. |
TBA |
| 9216843 |
32 |
Lanthionine-somatostatin analogs: synthesis, characterization, biological activity, and enzymatic stability studies. |
University of California San Diego |
| 25619419 |
5 |
Tampering with cell division by using small-molecule inhibitors of CDK-CKS protein interactions. |
Universit?? Pierre Et Marie Curie |
Search and Browse
